Photo by dawson2406 from unsplash
COVID‐19 convalescent plasma (CCP) was approved under emergency authorization to treat critically ill patients with COVID‐19 in the United States in 2020. We explored the demographics of donors contributing plasma… Click to show full abstract
COVID‐19 convalescent plasma (CCP) was approved under emergency authorization to treat critically ill patients with COVID‐19 in the United States in 2020. We explored the demographics of donors contributing plasma for a hyperimmune, plasma‐derived therapy to evaluate factors that may be associated with anti‐SARS‐CoV‐2 antibody response variability and, subsequently, antibody titers.
Keywords:
240 source;
analysis 240;
plasma;
plasma donors;
source plasma;
antibody
Journal Title: Journal of Clinical Apheresis
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Apheresis
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!